Cybin

100 articles with Cybin

• Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference

  3/8/2023

  Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference taking place on March 13-15, 2023.

• Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

  3/2/2023

  Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest ® Conference.

• Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

  2/28/2023

  Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® today announced significant progress updates for its two lead clinical development programs.

• Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

  2/1/2023

  Cybin Inc. is pleased to announce that it has received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule CYB004 through a protocol amendment to its ongoing CYB004-E Phase 1 trial.

• Cybin to Host Virtual R&D Day on February 28, 2023

  1/26/2023

  Cybin Inc. today announced that it will host a virtual R&D Day on Tuesday, February 28, 2023, from 10:00 a.m. ET to 11:30 a.m. ET.

• Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

  1/18/2023

  Cybin Announces Promising Results from Sponsored Kernel Flow ® Feasibility Study Measuring Psychedelic Effects on the Brain.

• Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

  1/12/2023

  Cybin Inc. today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004.

• Cybin Highlights 2022 Accomplishments and Milestones

  12/20/2022

  Cybin Inc. is pleased to provide a year-end summary of its key milestone accomplishments in 2022.

• Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting

  12/6/2022

  Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place December 4-7, 2022, in Phoenix, Arizona.

• Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

  11/15/2022

  Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company) today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (“SFN”) taking place November 12-16, 2022, in San Diego, CA.

• Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

  11/10/2022

  Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“DMT”) has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues.

• Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

  11/3/2022

  Cybin Inc. is pleased to announce its participation in the following upcoming investor events.

• Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit

  11/1/2022

  Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit.

• Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds

  9/27/2022

  Cybin Inc. has entered into an agreement with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules from Mindset (the “Agreement”).

• Mindset Pharma Provides Strategic Intellectual Property License to Cybin

  9/27/2022

  Mindset Pharma Inc. today announced an exclusive licensing agreement for Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) to acquire intellectual property rights for a subset of Mindset’s preclinical compounds (the “Agreement”).

• Cybin to Participate in Upcoming Scientific and Investor Conferences

  9/21/2022

  Cybin Inc. is pleased to announce its participation in the following upcoming conferences.

• Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

  9/20/2022

  Cybin Inc. announced that it has successfully achieved its research and development milestones that helped to build and progress its innovative pipeline of investigational psychedelic therapeutics ahead of projected timelines.

• Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

  8/30/2022

  Cybin Inc. is pleased to announce that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder.

• Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  8/25/2022

  Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference.

• Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

  8/17/2022

  Cybin Inc. and Clinilabs Drug Development Corporation today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to support the first-in-human Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog that is being developed for the treatment of major depressive disorder (“MDD”).